AML1 (RUNX1) encodes a DNA-binding subunit of the CBF transcription factor family and is required for the establishment of definitive hematopoiesis. AML1 is one of the most frequently mutated genes associated with human acute leukemia, suggesting that genetic alterations of the gene contribute to leukemogenesis. Here, we report the analysis of mice carrying conditional AML1 knockout alleles that were inactivated using the Cre/loxP system. AML1 was deleted in adult mice by inducing Cre activity to replicate AML1 deletions found in human MDS, familial platelet disorder and rare de novo human AML. At a latency of 2 months after induction, the thymus was reduced in size and frequently populated by immature double negative thymocytes, indicating defective Tlymphocyte maturation, resulting in lymphatic diseases with 50% penetrance, including atypical hyperplasia and thymic lymphoma. Metastatic lymphomas to the liver and the meninges were observed. Mice also developed splenomegaly with an expansion of the myeloid compartment. Increased Howell-Jolly body counts indicated splenic hypofunction. Thrombocytopenia occurred due to immaturity of mini-megakaryocytes in the bone marrow. Together with mild lymphocytopenia in the peripheral blood and increased fractions of immature cells in the bone marrow, AML1 deficient mice display features of a myelodysplastic syndrome, suggesting a preleukemic state.
Introduction
The AML1 gene encodes the acute myeloid leukemia 1 protein (AML1) or Core binding factor alpha 2 subunit (Cbfa2) (Levanon et al., 1994) . As a master regulatory protein AML1 controls the formation of definitive hematopoietic stem cells (HSCs) (Okuda et al., 1996; Wang et al., 1996a, b) and is required for the establishment of definitive hematopoiesis (Wang and Speck, 1992; Ogawa et al., 1993a; Miller et al., 2001 ) through the regulation of various hematopoietic genes (Rowley, 1998; Roumier et al., 2003) . Its expression is regulated in a cell-type and maturation-stage specific manner (Lorsbach et al., 2004) .
AML1 is one of the genes most frequently deregulated in human acute myeloid leukemia through different mechanisms including translocation, mutation and gene amplification (Roumier et al., 2003) , and is a target for loss of heterozygosity (LOH), suggesting that AML1 may act as a classical tumor suppressor gene (TSG) (Silva et al., 2003) . As chromosomal rearrangements are associated with up to 30% of acute leukemias, studies in mice and humans have focussed on the role of translocations in leukemogenesis (Yergeau et al., 1997; Okuda et al., 1998; Buchholz et al., 2000; Rhoades et al., 2000; Higuchi et al., 2002) . Recently, new mechanisms of AML1 deregulation by point mutations or amplification have been reported (Osato et al., 1999) . Point mutations within the Runt homology domain have been identified as the underlying cause for familial platelet disorder (FPD) with a predisposition to AML, and in rare cases as somatic events of de novo AML and myelodysplastic syndromes (Osato et al., 1999; Imai et al., 2000; Preudhomme et al., 2000; Michaud et al., 2003; Roumier et al., 2003; Taketani et al., 2003; Steensma et al., 2005) . AML1 point mutations that clustered in the Runt domain included silent mutations, heterozygous missense mutations and biallelic nonsense or frameshift mutations (Osato et al., 1999) .
The effect of AML1 deregulation by AML1 mutations has also been studied in transgenic mouse models. Homozygous deletion of either AML1 or CBF results in embryonic lethality. AML1 À/À embryos die from an absence of definitive hematopoiesis, central nervous system hemorrhages and necrosis (Okuda et al., 1996; Wang et al., 1996a; North et al., 1999) . Haploinsufficiency of AML1 causes an autosomal dominant congenital platelet defect due to defective megakaryopoiesis and predisposes to the acquisition of additional mutations resulting in leukemia (Song et al., 1999; Sun and Downing, 2004) .
Embryonic lethality of AML1 À/À mutant mice makes it impossible to study the function of AML1 in the adult organism. Only recently this problem has been addressed by two studies generating mice with conditional AML1 knockout alleles under the control of different promoters (Taniuchi et al., 2002; Ichikawa et al., 2004) . The AML1 knockout in early T-cell progenitors by use of the lck promoter showed that AML1 is required for CD4 silencing in double-negative (DN) CD4 À CD8 À thymocytes, for b selection of DN thymocytes, and CD8 upregulation (Taniuchi et al., 2002) . Ichikawa et al. (2004) reported a conditional knockout of AML1 in transgenic Mx-Cre mice, providing Cre activity after induction in a wide range of hematopoietic cells. In this study, mice lacking AML1 only showed minor effects on hematopoiesis, including a reduced number of platelets and mature lymphocytes in the peripheral blood, suggesting that AML1 is necessary for the proper maturation of lymphocytes and megakaryocytes, but dispensable for other myeloid lineage cells. An expansion and altered in vitro growth characteristics of the myeloid progenitor population were observed, as well as an expansion of the most immature progenitor population in the BM, indicating either a larger pool of stem cells, or an inhibition of their differentiation. For the maintenance of HSCs, AML1 was not necessary. However, structural and functional defects of hematopoietic organs were not reported.
Here, we report the generation of mice carrying a loxP-flanked exon 5 of the AML1 gene (AML1 fl/fl ). The usage of the interferon-responsive Mx-promoter for sitespecific recombination at the loxP sites enabled us to efficiently delete exon 5 in the hematopoietic system of adult mice by treatment of the mice with PolyIPolyC. In contrast to Ichikawa et al. (2004) , our study concentrates on the progression of the phenotype at later timepoints after the induction of the AML1 deletion. About 2 months after PolyIPolyC treatment, we observed a striking phenotype in Mx-Cre excised AML1 (AML1 D/D ) mice including progressive splenomegaly with an expansion of the myeloid compartment at the expense of the white pulp and signs of splenic hypofunction. Together with cytopenia in the peripheral blood and increased fractions of immature cells in the BM, we observed features of a myelodysplastic syndrome, suggesting a preleukemic state. Thymus size was reduced with a frequent shift of the thymocyte populations towards the very immature DN CD4 À
CD8
À fraction. In some AML1 D/D mice, we observed the development of thymic atypical hyperplasia or metastatic lymphoma. Therefore, our study shows that the lack of AML1 severely affects the structure and function of hematopoietic organs.
Results
Generation of mice carrying loxP sites in introns of the AML1 gene To study the function of the murine AML1 gene in adult mice, we generated mice with an AML1 targeting construct ( Figure 1a ). The floxed exon 5 contains part of the runt homology domain responsible for heterodimerization with the beta subunit and DNA binding (Ogawa et al., 1993b; Wang et al., 1996b) . Since a Cterminal truncation of AML1 is sufficient to disrupt DNA-binding and heterodimerization with CBFb (Lenny et al., 1995) , and partial loss of the runt domain (aa 143-178) destroys the ability of AML1 to bind DNA and heterodimerize with the CBFb subunit (Wang et al., 1996a) , deletion of exon 5 is expected to result in a functional AML1 knockout.
To evaluate recombination efficiency after PolyIPolyC treatment, we established a triple-primer PCR assay with primers annealing to the AML1 gene ( Figure 1a , primers P5 þ P6 þ P7). In the targeted AML1 alleles we (a) Scheme for induction of homologous recombination by Cre recombinase including loxP sites (triangle), neomycin cassette (neo), and annealing point of primers for PCR. Scheme shows the AML1 wild-type allele (top), the AML1 targeting construct before (middle, floxed (fl)) and after Cre-mediated sitespecific recombination of the loxP cassette (bottom, deleted(D)) due to treatment with the interferon-inducer PolyIPolyC. Recombination of the loxP cassette results in deletion of exon 5 of the murine AML1 gene. (b) Genotyping of ES cell clones. Result of PCR using primers P3 þ P4 with clones #1 and 2 (negative) and clones #3 and 4 (positive) are shown. (c-e) Genotyping of cells from hematopoietic organs after injection of mice with the PolyIPolyC. Tripleprimer PCR reactions were performed with primers P5 þ P6 þ P7 (see Table 1 (Figure 1c ). The intensity of the 382 bp band increases with the amount of recombined DNA in the reaction. The ratio of the band intensities can be used to determine the approximate recombination efficiency. Analysis of Cre-mediated recombination in the peripheral blood of AML1 D/D mice showed that recombination increased over time (Figure 1d cells. We, then, tested the efficiency of recombination in different organs (Figure 1e ). Recombination was strongest in the BM, followed by spleen, liver and thymus. Before PolyIPolyC treatment, no recombination was detectable (Figure 1d , lane pre), confirming that Cre recombinase is not expressed in untreated mice. Heterozygous AML1 fl/ þ and homozygous AML1 fl/fl mice were viable with no obvious anatomical or behavioral defects.
Adult AML1
D/D mice develop thrombocytopenia Complete blood cell counts were performed weekly after PolyIPolyC injections. Already one week after the first injection (PolyIPolyC was injected three times in twoday intervals), the number of thrombocytes in the peripheral blood of AML1 D/D mice had significantly decreased compared to AML1 fl/fl control mice (Figure 2a , t-test, 1st week: Po0.05; 2nd-6th week: Po0.01). Investigations of the BM of AML1 D/D mice revealed the presence of megakaryocytes, which were reduced in number and size (so called 'micromegakaryocytes'). May-Gru¨nwald/Giemsa-stainings confirmed the reduction of thrombocytes and occasionally revealed the presence of Howell-Jolly bodies in peripheral blood smears (Figure 2b) . Red blood cells containing Howell-Jolly bodies indicate an impaired clearance by the splenic vascular system (Morohashi et al., 1999) . More than 2 months after PolyIPolyC injection, 0.51% of the erythrocytes of AML1 D/D mice contained HowellJolly bodies compared to 0.16% in control mice (n AML1fl/f ¼ 6, n AML1D/D ¼ 6; t-test: Po0.001), suggesting impaired splenic function.
White blood cell (WBC) counts varied, with no dramatic increase in numbers observed within 4 months after the deletion of exon 5 of AML1. In contrast, number of lymphocytes were reduced in AML1 D/D mice 4 weeks after the first PolyIPolyC injection (Figure 2c , t-test, 3rd-4th week: Po0.01; 5th week: Po0.05, 6th week: Po0.01). The number of monocytes, granulocytes, erythrocytes and the hemoglobin level of AML1 D/D mice were not affected (data not shown). Pappenheim method (May-Gru¨nwald/Giemsa-stain), Peroxidase stains, and Alpha-naphthyl acetate esterase stains of peripheral blood smears showed no obvious number of blast cells, but differentiated cells of all types of WBCs (data not shown). Thus, deletion of AML1 in adult mice had no dramatic effect on cellularity in the peripheral blood, except for thrombocytopenia and moderate lymphocytopenia.
AML1
D/D mice develop splenomegaly and lymphomas Pathological analysis revealed that AML1 D/D mice develop splenomegaly (Figure 2d ). During the first 7 weeks after injection of PolyIPolyC, an increase in spleen size was only observed sporadically with no statistically significant difference between AML1 D/D and control mice (n AML1fl/fl ¼ 4, n AML1D/D ¼ 5, t-test: p ¼ n.s.). More than 7 weeks after PolyIPolyC treatment, however, the increase of spleen weight in AML1 D/D mice was highly significant, with spleen body weight ratios up to 0.010 (see Table 1 ), suggesting that a progression of splenomegaly positively correlated with the time span of the induced deletion (n AML1fl/fl ¼ 31, n AML1D/D ¼ 28; t-test: Po0.001; Figure 2d ).
Analysis of the spleen architecture showed a reduced and dispersed white pulp with a striking expansion of the red pulp compartment in AML1 loÀhi cell fraction (Lagasse and Weissman, 1996) . As the numbers of granulocytes and monocytes in the peripheral blood of AML1 D/D mice did not differ from control mice, the accumulation of immature myelomonocytic cells appear to result from an enlarged pool of myeloid progenitors, but not from a fl/fl 5.3%). Splenomegaly, therefore, appears to result from increased extramedullary hematopoiesis in the spleen, which leads to an expansion of the red pulp . Besides the described cell populations, lymphocytes and minimegakaryocytes, increased numbers of mast cells were found within the red pulp of the AML1 D/D mice. Goldner's staining failed to show increased fibrosis of the spleen, and vascular neoplasms were excluded by immunofluorescence for CD31 (data not shown). This along with normal hemoglobin values and erythrocyte counts suggests that the observed functional hyposplenism is due to an immaturity of the macrophages.
In contrast, the relative numbers of B-cells in the spleen were found to be reduced in AML1 
CD8
À cells, indicating a block in T-cell maturation.
To study whether a block in T-cell maturation is also observed in the thymus, we investigated structure and cellularity of this organ. Most AML1 D/D mice appeared to have smaller thymuses than control mice (Figure 5a 2.4%) were strongly reduced. In AML1 D/D mice with a reduced thymus, the overall number of thymic cells was severely reduced. These results confirm a block in T-cell maturation in the thymus, and may explain lymphocytopenia in the peripheral blood.
At histological examination, the distinction between thymic medulla and cortex was lost in two of the six AML1 D/D mice studied (Figure 5c-e) . In both mice, the medulla was populated by immature lymphoblasts at 98 days after PolyIPolyC treatment. In one case this was confined to the thymus (Figure 5d ). This along with a small size of the affected thymic lobe has previously been reported as atypical hyperplasia in chemically induced lymphoma (Dunnick et al., 1997) . In the other case, lymphoblasts expanded beyond the thymic capsule (Figure 5e and f) and metastasized to the liver, representing a metastatic thymic lymphoma. Another mouse had histological evidence of a malignant lymphoma of a cervical lymph node metastatic to the brain (Figure 5g-j) . Described lymphomas were negative for B-cell marker B220, and are therefore assumed to be Tcell lymphomas (data not shown). No lymphomas were found in age-and induction-matched control mice. In mice without lymphoid neoplasms, the secondary follicles in peripheral lymph nodes and Peyer's patches of AML1 D/D mice were either very small compared to the AML1 fl/fl mice, or completely missing. This might indicate a reduced activation of B lymphocytes in absence of mature T lymphocytes.
To analyse whether the partial deletion of the AML1 gene affects cellularity in the BM, FACS analysis was performed. We observed a eight-fold increase of the Sca-1 þ c-Kit þ population in the total BM of AML1 excised animals compared to control mice (data not shown). Flow cytometry analysis of lineage-negative depleted BM cells revealed an increased fraction of HSCs (Figure 4k fl/fl mice) 5 weeks after injection of PolyIPolyC, which indicated either increased proliferation of hematopoietic stem and progenitor cells or a block in the maturation of hematopoietic progenitors.
Discussion
The AML1 gene is one of the most frequently mutated genes in human leukemias. Investigation of AML1 mutations in transgenic mouse models, therefore, might help to understand the role of AML1 in hematopoiesis and its leukemogenic potential. The inducible Table 1 , Supplement).
AML1
D/D mice develop splenomegaly and lymphomas G Putz et al deletion of AML1 in adult mice enabled us to circumvent embryonic lethality and to recapitulate the situation found in human cancers where mutations are believed to occur during later stages of development.
In the first weeks after deletion of AML1, we observed a mild phenotype including thrombocytopenia and slight lymphocytopenia in the peripheral blood, together with an expansion of progenitor populations in the BM, supporting the idea that AML1 is essential for the AML1 D/D mice develop splenomegaly and lymphomas G Putz et al development of megakaryocytes and the terminal differentiation of T-lymphocytes. The short-term phenotypical changes in adult AML1 D/D mice were surprisingly mild compared to the severe defects of AML1 mutations during embryogenesis. In contrast, at longer latency, mice developed progressive splenomegaly due to the enlargement of the red pulp compartment resulting from myelomonocytic cell expansion. The white pulp compartment was decreased in size with a relatively reduced population of lymphoid cells. The enlargement of the spleen led to splenic hypofunction, accompanied by the presence of Howell-Jolly bodies in erythrocytes of the peripheral blood. The association of splenomegaly and functional hyposplenism is rare. We suggest that the observed functional hyposplenism is due to an immaturity of the splenic macrophages.
According to the Bethesda proposal of classification of nonlymphoid hematopoietic neoplasms in mice (Kogan et al., 2002) , we observed a myelodysplastic syndrome. Criteria for diagnosis were thrombocytopenia without leukocytosis or erythrocytosis, together with dysplastic megakaryocytes, and the exclusion of a nonlymphoid leukemia. In human myelodysplastic syndromes a multistep progression to AML is documented by serial acquisition of cytogenetic abnormalities associated with progression of disease (Hirai et al., 1987; Hirai et al., 1988; Rowley, 1998) . Splenomegaly has been reported in MDS-AML patients (Bourgeois et al., 2001) . The finding of splenomegaly in our mice, might, therefore, indicate a commencing progression of the myeloid dysplasia. Further investigation of AML1 D/D mice during late stages of adulthood will show whether preleukemic mice finally will develop a type of leukemia.
The observation of smaller thymuses, which mainly contained immature DN thymocytes, indicate a block in T-cell maturation and explain lymphocytopenia in the peripheral blood. These results are in accordance to Ichikawa et al. (2004) , who found no reconstitution of thymocytes in recipients of a competitive repopulation assay, suggesting a block in T-cell maturation. Concluding from our detailed analysis of thymus cellularity and architecture in AML1 D/D mice; however, we do not hypothesize an accumulation of precursors in the thymus, but rather the apoptosis of thymocytes prior to maturation. The observation of a reduction of the total number of thymocytes goes along with results from a conditional AML1 knockout under control of the Tcell specific lck-Cre promoter. In this study, however, the dramatic shift from DP to DN thymocytes, which we observed in AML1 D/D mice, had not been documented (Taniuchi et al., 2002) . In contrast, Taniuchi et al. (2002) reported the requirement of AML1 for CD4 repression in DN thymocytes. These discrepancies might appear, because lck-Cre expression becomes evident at a relatively late stage of development of immature DN thymocytes, while Mx-Cre expression reveals the effects of lacking AML1 at earlier stages of thymocyte development. In three of six AML1 D/D mice studied in detail, prelymphomas or lymphomas originated in the thymus or in peripheral lymph nodes and metastasized to the liver or the brain. With our mouse model, we show that AML1 plays an important role in the control of hematopoietic cell maturation in adult mice, and that the lack of AML1 in hematopoietic cells leads to a defective architecture and function of hematopoietic organs and, at longer latency, to lymphoid neoplasms.
Haploinsufficiency of murine AML1 was characterized by a slight reduction of the number of platelets in the peripheral blood of 15%, compared to a 50% reduction in AML1 D/D mice. No abnormalities were detected in the number of myeloid and lymphoid cells in the periperal blood or spleen of AML1 haploinsufficient mice . The different phenotypes are suggesting that expression of 50% of the normal amount of AML1 is sufficient to regulate myeloid cell proliferation and lymphoid cell differentiation, but not to compensate for defective megakaryopoiesis.
The defects of AML1 deletion in adult mice also varied from those observed in the AML/ETO translocation. Although in vitro growth characteristics of multilineage hematopoietic progenitors were altered in mice lacking AML1, apparent in an increased self-renewal capacity (Ichikawa et al., 2004) , AML1-deficiency did not lead to the immortalization of myeloid progenitors, observed in AML/ETO expressing cells (Okuda et al., 1998; Rhoades et al., 2000; Yuan et al., 2001; Higuchi et al., 2002) . Also thrombocytopenia and mild lymphocytopenia seem to be characteristic for the loss of . The distinction between the cortex and the medulla can be easily seen. (d) Atypical hyperplasia reduces the cortical/medullary distinction but is confined to the thymus (H&E, Â 100). (e) Thymic lymphoma (H&E, Â 100). A mixed cell population of immature lymphoid cells extends beyond the thymic capsule. Large pink thymic cysts as seen in the center occur sporadically in normal mice (Fredrickson and Harris, 2000) . (f) At higher power, lymphoblasts, mixed with few cortical lymphocytes and apoptotic bodies are seen at the invasion front (H&E, Â 400, zoom factor 1.6). Some lymphoblasts contain a central, round nucleolus. At the left edge, a large tingible body macrophage (white arrow) containing phagocytosed apoptotic tumor cells, and reflecting high rates of cell proliferation and cell death, is seen (starry sky appearance). The black arrows point at numerous mitotic figures. (g) Lymphoblastic lymphoma of an enlarged cervical lymph node (H&E, Â 50). The neoplastic cells destroy the architecture of the lymph node and extend beyond its capsule into the adjacent fat tissue. (h) Higher power (H&E, Â 400, zoom factor 1.6) revealed that the lymphoma cells formed sheets of uniform medium-sized cells with round nuclei, a fine chromatine structure, a prominent central nucleolus or small scattered nucleoli, and a high mitotic rate (arrows: mitotic figures). (i) Metastases of the lymphoma shown in (h) to the meninges and the brain (H&E, Â 50). (j) Starting perivascular, the lymphoblasts diffusely infiltrate the brain cortex (H&E, Â 400). The vessel wall appears intact. The hemorrhage into the liquor occurred perimortally. The inset shows a similar cytology as in (h).
D/D mice develop splenomegaly and lymphomas G Putz et al AML1, whereas no abnormalities were found in the blood cell counts of mice with the translocation (Higuchi et al., 2002) . While we could show that the lack of AML1 in the hematopoietic system affected the structure and function of the spleen and the thymus, no histological abnormalities were found in any of the hematopoietic organs in conditional AML/ETO knockin mice where AML/ETO expression was driven off of the endogenous AML1 regulatory sequences (Higuchi et al., 2002) . In contrast, splenomegaly with an increase of immature myeloid populations as well as the development of lymphomas were described in leukemic AML/ETO mice after ENU treatment (Yuan et al., 2001) . Thus, with the AML1 deletion, we are able to dissect the role of AML1 from the dominant-negative effects of the AML-ETO fusion protein and from effects caused by altered ETO expression.
Altogether, our mouse model is a valuable tool to study the role of AML1 in the adult mouse and to investigate the mechanisms underlying the development and progression of myelodysplastic syndromes. The conditional AML1 knockout allele enables us to study what cooperative events support the development of AML1-related hematopoietic neoplasms.
Materials and methods

Generation of transgenic mice
The AML1 targeting construct (Figure 1a) was generated by inserting a neomycin cassette flanked ('floxed') by loxP sites downstream of exon 5 of AML1 and by inserting a loxP site upstream of exon 5 of the AML1 gene. E14 embryonic stem (ES) cells were electroporated with the targeting construct and clones were selected. Genotyping was performed by PCR ( Figure 1a and b, primers P3 þ P4, see the Supplemental Materials link at the top of the online article). Correctly targeted ES cell clones were used for blastocyst injections; one chimera transmitted the targeted allele through the germline. Mice positive for the floxed AML1 allele (AML1 fl/ þ ) were obtained by breeding and crossed to each other on C57/ BL6 Â 129SvJ background. The offspring was screened for homozygosity (primers P1 þ P2, P5 þ P6). AML1 fl/fl mice were then crossed to interferon-responsive Mx-Cre mice, and genotyped (primers P8 þ P9, Supplemental Materials). Cremediated site-specific recombination of the loxP cassettes was induced by three intraperitoneal injections of 300 mg PolyIPolyC (Sigma Aldrich Chemie GmbH, Taufkirchen, Germany) in 2-4 months old AML1 fl/fl mice at two-day intervals (Kuhn et al., 1995) . AML1 fl/fl mice lacking the Cre gene were treated the same way and used as control mice. All animal experiments were conducted in a licensed animal facility in accordance with the German Animal Welfare Act (Tierschutzgesetz), following the guidelines of the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (1986). Mice were kept under specific pathogen-free conditions. Serological testing for viruses was negative.
Genotype analysis
Mice were genotyped by PCR to detect both the wild-type and alleles of the AML1 targeting construct. Genomic DNA was isolated from tail biopsies and subjected to PCR primers (primers P1 þ P2, P3 þ P4, P5 þ P6, P8 þ P9, Supplemental Materials). PCR products were resolved by agarose gel electrophoresis. To test for recombination in murine tissue, DNA of peripheral blood, BM, spleen, liver, kidney and thymus was isolated by phenol chloroform extraction and genotyped by PCR analyses (triple primer PCR assay with primers P5 þ P6 þ P7).
Flow cytometry analysis FACS analysis and cell sorting were performed using the BD FACSAria Cell-Sorting System. Murine spleen and BM cells were stained with rat anti-mouse Sca-1 (Ly6A/E), CD117 (c-Kit), Prominin-1 (13A4), CD4 (L3T4), CD8 (Ly-2), B220 (CD45R), IgM, Gr-1 (Ly6G), CD11b (Mac1). All cells were blocked with purified rat anti-mouse CD16/CD32 monoclonal antibody (Mouse BD Fc Block). As isotype control, we used R-Phycoerythrin-conjugated rat IgG 2a,k monoclonal immunoglobulin isotype control, Fluorescein Isothiocyanate-conjugated rat IgG 2b,k monoclonal immunoglobulin isotype control, and PE-Cy5-conjugated rat IgG 2a,k monoclonal immunoglobulin isotype control. Antibodies, except for Prominin-1, were purchased from BD Biosciences Pharmingen (Erembodegem, Belgium) and are listed in the Supplemental Materials link. Prominin-1 was ordered from eBioscience (San Diego, CA, USA). For lineage depletion of BM cells the Miltenyi Lineage Cell Depletion Kit (#130-090-858) was used, followed by Magnetic separation with Miltenyi MACS LS Columns and MACS Separator (Miltenyi Biotec, Bergisch Gladbach, Germany). FACS analysis was done on multiple mice (for details see Supplemental Materials link). Figures show mice representative for the analysis.
Hematological analysis
Peripheral blood was withdrawn from mice via saphenous vein puncture and collected in tubes containing EDTA. Complete blood counts were performed weekly using the HEMAVET HV 850FS analyzer (CDC Technologies, Oxford, CT, US). Cells were stained by using the Pappenheim method (May-Gru¨nwald/Giemsa-stain), Peroxidase, and Alphanaphthyl acetate esterase stain. Counts of erythrocytes containing Howell-Jolly bodies were performed by counting X1000 erythocytes per investigated mouse.
Histologic and immunohistochemical analysis
At various time-points after PolyIPolyC injections, mice were sacrificed by CO 2 asphyxiation. Selected organs, including spleen, thymus and BM were removed. Complete necropsies with emphasis on the hematopoietic system were performed in six AML1 D/D mice and six AML1 fl/fl control mice matched for age, sex and PolyI-PolyC-injection time. For a determination of organ size, organs were trimmed of fat and connective tissues and weighed. Tissues processed for microscopic evaluation were fixed in 10% neutral-buffered formalin, embedded in paraffin, sectioned (4-mm sections), mounted on slides and stained with hematoxylin and eosin. Goldner's trichrome staining was performed as previously described (Schiering et al., 1999) . Bone was decalcified using Ossa fixona (Waldeck GmbH, Munster, Germany). Metachromatic mast cell granula were visualized by Toluidine blue staining.
For immunohistochemistry, frozen spleen fragments were embedded in Tissue-tek medium (Science Services, Munich, Germany), cut, air-dried, fixed in acetone or methanol, washed in PBST containing 0.1% Tween 20, and blocked with 2% BSA. Sections were incubated with purified anti-CD4 (L3T4), anti-B220 (CD45R), anti-Gr1 (Ly6G), or anti-CD11b (Mac1) from BD Biosciences PharMingen, followed by Cy3 AffiniPure F(ab 00 )2 Frag Donkey Anti-Rat IgG (Jackson Immuno- 
Statistical analysis
The Student's t-test was used to determine the statistical differences between various experimental and control groups. The difference was considered statistically significant when *Po 0.05 or **Po0.01.
